Investor InterestAnalyst remains optimistic that phase 1 dose-expansion outcomes with Werewolf's tumor-conditional IL-2, WTX-124, will drive investor interest.
Pipeline EvolutionWerewolf's latest update marks a clear step forward in the evolution of its pipeline, with progress across all three of its active programs.
Regulatory EngagementWerewolf plans to engage with regulatory authorities to discuss potential registrational pathways for WTX-124 in advanced cutaneous melanoma.